Carlos Perez, MD
Family Medicine · Coral Gables, FLNPI 1528225638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $405 and has fallen 84.1% since, to $64 in 2025.
Across 40 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$97
- Sumitomo Pharma America, Inc.$71
- Exact Sciences$66
- AstraZeneca$59
- Eisai Inc.$54
- Amgen$50
- plus $367 from 15 others
Across 110 payments — averaging $7024.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$466K
- Chiesi USA, Inc.$92K
- GSK$72K
- Sanofi US Services Inc.$54K
- Janssen Research & Development, LLC$32K
- Boehringer Ingelheim Canada Ltd.ltee$26K
- plus $31K from 2 others
What the payments were for
- Food & beverage$763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $97 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Exact Sciences | 3 | $66 |
| AstraZeneca(2 entities) | 3 | $59 |
| Eisai Inc. | 3 | $54 |
| Amgen | 3 | $50 |
| Novo Nordisk | 2 | $40 |
| Bayer | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $24 |
| AbbVie | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Pfizer | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
How this compares
$763 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $130,641 |
| MounjaroTirzepatide | 70 | $79,011 |
| JardianceEmpagliflozin | 62 | $53,119 |
| RybelsusSemaglutide | 46 | $45,491 |
| EliquisApixaban | 38 | $29,474 |
| JanuviaSitagliptin Phosphate | 42 | $27,117 |
| SynthroidLevothyroxine Sodium | 288 | $24,624 |
| FarxigaDapagliflozin Propanediol | 25 | $19,699 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $17,824 |
| TrulicityDulaglutide | 12 | $16,601 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $16,498 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $16,277 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,913 |
| TradjentaLinagliptin | 22 | $11,982 |
| EntrestoSacubitril/Valsartan | 20 | $11,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $40 | $176,132172 claims |
| Lilly USA, LLCMounjaro, Trulicity | $97 | $95,61282 claims |
| AbbVieSynthroid, Linzess | $23 | $31,122300 claims |
| PfizerEliquis | $19 | $29,47438 claims |
| AstraZenecaFarxiga, Symbicort | $59 | $22,77338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Coral Gables
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.